Similar Search Results

Public subsidies for R&D and public sector pharmaceutical innovation

Kourouklis, Dimitrios - In: Applied economics 53 (2021) 32, pp. 3759-3777

Persistent link: https://www.econbiz.de/10012589537

The Structural Genomics Consortium : successful organisational technology experiment or new institutional infrastructure for health research?

Jones, Molly Morgan; Chataway, Joanna - In: Technology analysis & strategic management 33 (2021) 3, pp. 296-306

Persistent link: https://www.econbiz.de/10012501341

Generic competition and the incentives for early-stage pharmaceutical innovation

Branstetter, Lee; Chatterjee, Chirantan; Higgins, Matthew J. - In: Research policy : policy, management and economic … 51 (2022) 10, pp. 1-19

Persistent link: https://www.econbiz.de/10014229272

R&D grants and medical innovation

Unsal, Omer; Houston, Reza - In: Journal of economics and business 128 (2024), pp. 1-26

Persistent link: https://www.econbiz.de/10015066027

Special FDA designations for drug development : orphan, fast track, accelerated approval, priority review, and breakthrough therapy

Michaeli, Daniel; Michaeli, Christoph T.; Albers, Sebastian - In: The European journal of health economics 25 (2024) 6, pp. 979-997

Persistent link: https://www.econbiz.de/10014633366

The innovative platform programme in South Korea : economic policies in innovation-driven growth

Kim, Seong Soo; Choi, Yo Sop - In: Foresight and STI governance : journal of the National … 13 (2019) 3, pp. 13-22

After several decades of rapid development, South Korea has recently experienced a critical economic downturn. The paper considers the prerequisites for the current state-of-the-art, as well as the new economic policy agenda aimed at fostering innovation in various sectors, thereby suggesting...

Persistent link: https://www.econbiz.de/10012160301